Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Belgian scientists in Nature with cancer breakthrough

Scientists Peter Carmeliet and Sarah-Maria Fendt (KU Leuven/VIB) published in the prestigious Nature journal on their fundamental breakthrough in …


ThromboGenics and VIB found oncology company

Oncurious is a new oncology company that will perform clinical trials for the development of TB-403. This compound is a new promising agent for…


Congrats to Biocartis!

The Mechelen-based biotech company Biocartis starts its IPO adventure. The demand for shares was 6,5 times higher than the offer. Biocartis gather…

POPULAR TAGS

BioWin launches two innovative projects to treat breast cancer and liver diseases

Written by DS on in the category news with the tags , .


Two BioWin projects were launched a few weeks ago. The first of these, “TreatBest”, involves a consortium made up of Diagenode, IDDI, the Université Libre de Bruxelles (ULB), the Institut Jules Bordet and the University of Liège. The consortium members are pooling their expertise to support the “disruptive” science being developed at the ULB in the field of personalised breast cancer treatment. The aim of this project is to clinically validate an in vitro diagnostic test (with CE marking) that can predict the benefit of prescribing a standard anthracycline and taxane-based chemotherapy treatment for patients suffering from triple-negative breast cancer, the most aggressive form of the disease. This test will help clinicians to select the most appropriate treatment for each patient and reduce undesirable side effects, in the hope of improving their chances of recovery. The budget for this project is € 3,662,684.

The second project, “Improve”, is being led by Promethera Biosciences, a biopharmaceutical company that develops innovative cell therapies for treating liver diseases. The company is now focusing on widespread diseases with a view to expanding its product pipeline. The aim of the Improve project is to validate, at the preclinical stage, a new cell therapy product that will be ready to enter the clinical phase for the treatment of chronic fibroinflammatory liver diseases. To ensure that this project is a success, Promethera is drawing on the expertise of ImmunXperts, the paediatric hepatology laboratory and Institute for Experimental and Clinical Research (Hepato-Gastroenterology Unit) at the Université Catholique de Louvain (UCL) and the Institut Meurice. The Improve project has got a budget of € 1,269,731.

 

 

Read more about: , .

RELATED ARTICLES
Belgian scientists in Nature with cancer breakthrough

Scientists Peter Carmeliet and Sarah-Maria Fendt (KU Leuven/VIB) published in the prestigious Nature journal on their fundamental breakthrough in …


ThromboGenics and VIB found oncology company

Oncurious is a new oncology company that will perform clinical trials for the development of TB-403. This compound is a new promising agent for…


Congrats to Biocartis!

The Mechelen-based biotech company Biocartis starts its IPO adventure. The demand for shares was 6,5 times higher than the offer. Biocartis gather…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Turnstone Biowin Janssen GSK UGent V-Bio Ventures Flanders.bio XpandInnovation Itera Life Science KU Leuven

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.